The estimated Net Worth of Marilyn J. Purchase is at least $3.29 Milion dollars as of 9 April 2015. Marilyn Purchase owns over 28,000 units of Amphastar Pharmaceuticals Inc stock worth over $3,285,693 and over the last 10 years Marilyn sold AMPH stock worth over $0.
Marilyn has made over 1 trades of the Amphastar Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Marilyn exercised 28,000 units of AMPH stock worth $414,400 on 9 April 2015.
The largest trade Marilyn's ever made was exercising 28,000 units of Amphastar Pharmaceuticals Inc stock on 9 April 2015 worth over $414,400. On average, Marilyn trades about 9,333 units every 0 days since 2014. As of 9 April 2015 Marilyn still owns at least 72,902 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Marilyn Purchase stock trades at the bottom of the page.
Marilyn's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins a William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: